Vol. 22 No. 4 (2009), Artykuły
Vol. 22 No. 4 (2009)

The use of UV-VIS spectroscopy for determiningthe photostability of epirubicin solutions

Artykuły
Published 2009-12-30
Przemysław Zalewski
Department of Pharmaceutical Chemistry
Artur Firlej
Department of Pharmaceutical Chemistry
Beata Medenecka
Department of Pharmaceutical Chemistry
Joanna Jankowska
Department of Pharmaceutical Chemistry
Jadwiga Mielcarek
Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences
Irena Oszczapowicz
Department of Modified Antibiotics, Institute of Biotechnology and Antibiotics, Warsaw

Abstract

Photostability of epirubicin – an anticancer drug – was investigated. The solution samples were exposed to UV-A and VIS radiation and the photodegradation process was monitored by using a spectrophotometric method. Epirubicin was shown to be photolabile and its photodegradation was a first-order reaction. The quantum yields of each photodegradation process were also calculated.

PDF

References

1. Aman W., Thoma K.: ICH guideline for photostability testing: aspects and directions for use. Pharmazie, 58, 877, 2003.

2. Benizri F., Bonan B., Ferrio A. L. et al.: Stability of antineoplastic agents in use for homebased intravenous chemotherapy. Pharm. World. Sci., 31, 1, 2009.

3. Dine T., Cazin J. C., Gressier B. et al.: Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm. Weekbl. Sci., 14, 365, 1992.

4. Hortobágyj G. M.: Anthracyclines in the treatment of cancer. An overview. Drugs, 54, 1, 1997.

5. Jelińska A., Zają c M., Krzysztoń K. et al.: The use of HPLC for determining the stability 48 P. Zalewski, A. Firlej, B. Medenecka, J. Jankowska, J. Mielcarek, I. Oszczapowicz of epirubicin and the influence of ionic strength on the stabili-ty of epirubicin. Annales UMCS Sect. DDD, 19, 45, 2006.

6. Minotti G., Menna P., Salvatorelli E. et al.: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185, 2004.

7. Pujol M., Munoz M., Prat J. et al.: Stability study of epirubicin in NaCl 0.9% injection.Ann. Pharmacother., 31, 992, 1997.

8. Rober t J.: Epirubicine. Clinical pharmacology and dose-effect relationship. Drugs, 45, 20, 1993.

9. Schimmel K., Richel D., van den Drink R., Guchelaar H.: Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev., 30, 181, 2004.

10. Tønnesen H. H.: Formulation and stability testing of photolabile drugs. Int. J. Pharm., 225, 1, 2001.

11. Wood M. J., Irwin W. J., Scott D.K.: Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high–performance liquid chromatography. J. Clin. Pharm. Ther., 15, 291, 1990.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2009 Authors

Downloads

Download data is not yet available.